Idorsia Investor Relations Material

Idorsia Ltd is a biopharmaceutical company based in Switzerland, specializing in the discovery, development, and commercialization of small molecules. The company targets a wide range of diseases, including Fabry disease, insomnia, resistant hypertension, cerebral vasospasm, epilepsy, nasal polyposis, and systemic lupus erythematosus, among others. Idorsia's approach spans multiple therapeutic areas such as CNS, cardiovascular, and immunological disorders, as well as orphan diseases. The company is headquartered in Allschwil, near Basel, Switzerland, and its shares are listed on the SIX Swiss Exchange.